TD Cowen Downgrades Crinetics Pharmaceuticals to Hold

Benzinga Newsdesk www.benzinga.com Negative 90.7%

Neg 90.7% Neu 0% Pos 0%

TD Cowen analyst Tyler Van Buren downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from Buy to Hold.

Comments

No comments yet. Be the first!